Strong anticonvulsant effect of thalidomide on amygdaloid kindling

Epilepsy Research

Volumn 95, Issue 3, 2011, Pages 263-269

  Palencia, Guadalupe ^a   Rubio, Carmen ^a   Custodio Ramirez, Veronica ^a   Paz, Carlos ^a   Sotelo, Julio ^a  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Complex seizures; Epilepsy therapy; Kindling; Refractory epilepsy; Thalidomide

Indexed keywords

THALIDOMIDE; TOPIRAMATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; KINDLING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE; WISTAR RAT;

AMYGDALA; ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; FRUCTOSE; HUMANS; KINDLING, NEUROLOGIC; MALE; RATS; RATS, WISTAR; SEIZURES; THALIDOMIDE;

EID: 79960380787     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2011.04.008     Document Type: Article

References (48)

1. Arrieta O., Palencia G., Garcia-Arenas G., Morales-Espinosa D., Hernandez-Pedro N., Sotelo J. Prolonged exposure to lead lowers the threshold of pentylenetetrazole-induced seizures in rats. Epilepsia 2005, 46:1599-1602.
2. Bergstroem R.M., Bergstroem L., Putkonen P., Sainio K. The effects of thalidomide on the electrical activity of the brain in the intrauterine guinea-pig foetus. Med. Exp. Int. J. Exp. Med. 1964, 11:119-127.
3. Bertram E. The relevance of kindling for human epilepsy. Epilepsia 2007, 48(Suppl. 2):65-74.
4. Borowicz K.K., Luszczki J.J., Duda A.M., Czuczwar S.J. Effect of topiramate on the anticonvulsant activity of conventional antiepileptic drugs in two models of experimental epilepsy. Epilepsia 2003, 44:640-646.
5. Calabrese L., Fleischer A.B. Thalidomide: current and potential clinical applications. Am. J. Med. 2000, 108:487-495.
6. Chen X., Bao G., Hua Y., Li Y., Wang Z., Zhang X. The effects of topiramate on caspase-3 expression in hippocampus of basolateral amygdala (BLA) electrical kindled epilepsy rat. J. Mol. Neurosci. 2009, 38:201-206.
7. Chim C.S., Lie A.K., Chan E.Y., Leung Y.Y., Cheung S.C., Chan S.Y., Liang R., Kwong Y.L. A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma. Ann. Hematol. 2010, 89:1019-1027.
8. Clark J.I., Moon J., Hutchins L.F., Sosman J.A., Kast W.M., Da Silva D.M., Liu P.Y., Thompson J.A., Flaherty L.E., Sondak V.K. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer 2010, 116:424-431.
9. Cuadrado M.J., Karim Y., Sanna G., Smith E., Khamashta M.A., Hughes G.R. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am. J. Med. 2005, 118:246-250.
10. De Sanctis J.B., Mijares M., Suárez A., Compagnone R., Garmendia J., Moreno D., Salazar-Bookaman M. Pharmacological properties of thalidomide and its analogues. Recent Pat. Inflamm. Allergy Drug Discov. 2010, 4(2):144-148.
11. Eells J.B., Clough R.W., Browning R.A., Jobe P.C. Comparative Fos immunoreactivity in the brain after forebrain, brainstem or combined seizures induced by electroschock, pentylenetetrazol, focally induced and audiogenic seizures in rats. Neuroscience 2004, 123:279-292.
12. Engel J. Clinical aspects of epilepsy. Epilepsy Res. 1991, 10:9-17.
13. Engel J., Wolfson L., Brown L. Anatomical correlates of electrical and behavioral events related to amygdaloid kindling. Ann. Neurol. 1978, 3:538-544.
14. Fisher R.S. Animal models of the epilepsies. Brain Res. Brain Res. Rev. 1989, 14:245-278.
15. Frederickson R.C., Slater I.H., Dusenberry W.E., Hewes C.R., Jones G.T., Moore R.A. A comparison of thalidomide and pentobarbital - new methods for identifying novel hypnotic drugs. J. Pharmacol. Exp. Ther. 1977, 203:240-251.
16. Friderichs E. Studies on the CNS activity profile of thalidomide analogs (author's transl). Arzneimittelforschung 1982, 32:613-620.
17. Fujiwara A., Watanabe Y., Takechi K., Ishikawa T., Kaida Y., Akagi M., Kamei C. The usefulness of olfactory bulb kindling as a model for evaluation of antiepileptics. Epilepsia 2010, 51:445-453.
18. Goddard G.V. Development of epileptic seizures through brain stimulation at low intensity. Nature 1967, 214:1020-1021.
19. Goddard G.V., McIntyre D.C., Leech C.K. A permanent change in brain function resulting from daily electrical stimulation. Exp. Neurol. 1969, 25:295-330.
20. Ionov I.D. Self-reinforcing loop mechanism in epilepsy. Med. Hypotheses 2009, 73:608-609.
21. Kanno O. Electroencephalographic study of 137 patients with thalidomide embryopathy. Jpn. J. Psychiatry. Neurol. 1987, 41:197-205.
22. Keller H., Kunz W., Muckter H. N-phthalyl-glutamic acid imide; experimental studies on a new synthetic product with sedative properties. Arzneimittelforschung 1956, 6:426-430.
23. Lehman T.J., Schechter S.J., Sundel R.P., Oliveira S.K., Huttenlocher A., Onel K.B. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study. J. Pediatr. 2004, 145:856-857.
24. Li G., Bauer S., Nowak M., Norwood B., Tackenberg B., Rosenow F., Knake S., Oertel W.H., Hamer H.M. Cytokines and epilepsy. Seizure Apr. 2011, 20(3):249-256.
25. Löscher W., Rundfeldt C., Hönack D. Pharmacological characterization of phenytoin-resistant amygdala-kindled rats, a new model of drug-resistant partial epilepsy. Epilepsy Res. 1993, 15:207-219.
26. McNamara J.O., Byrne M.C., Dasheiff R.M., Fitz J.G. The kindling model of epilepsy: a review. Prog. Neurobiol. 1980, 15:139-159.
27. Marjanovic B.D., Stojanov L.M., Zdravkovic D.S., Kravljanac R.M., Djordjevic M.S. Rasmussen syndrome and long-term response to thalidomide. Pediatr. Neurol. 2003, 29:151-156.
28. Medhi B., Prakash A., Avti P.K., Chakrabarti A., Khanduja K.L. Intestinal inflammation and seizure susceptibility: understanding the role of tumour necrosis factor-alpha in a rat model. J. Pharm. Pharmacol. 2009, 61:1359-1364.
29. Nakamura J., Tamura S., Kanda T., Ishii A., Ishihara K., Serikawa T., Yamada J., Sasa M. Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur. J. Pharmacol. 1994, 254:83-89.
30. Palencia G., Arrieta O., Ríos C., Altagracia M., Kravzov J., Sotelo J. Effect of thalidomide in different tumors in rodents. J. Exp. Ther. Oncol. 2002, 2:158-162.
31. Palencia G., Calderon A., Sotelo J. Thalidomide inhibits pentylenetetrazole-induced seizures. J. Neurol. Sci. 2007, 258:128-131.
32. Palencia G., Martinez-Juarez I.E., Calderon A., Artigas C., Sotelo J. Thalidomide for treatment of refractory epilepsy. Epilepsy Res. 2010, 92:253-257.
33. Parman T., Wiley M.J., Wells P.G. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat. Med. 1999, 5:582-585.
34. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, Sydney.
35. Privitera M.D., Brodie M.J., Mattson R.H., Chadwick D.W., Neto W., Wang S. EPMN 105 Study Group Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol. Scand. 2003, 107:165-175.
36. Racine R.J. Modification of seizure activity by electrical stimulation: cortical areas. Electroencephalogr. Clin. Neurophysiol. 1975, 38:1-12.
37. Rao R.S., Medhi B., Khanduja K.L., Pandhi P. Correlation of seizures and biochemical parameters of oxidative stress in experimentally induced inflammatory rat models. Fundam. Clin. Pharmacol. 2010, 24:325-331.
38. Ravenscroft A., Schoeman J.F., Pretorious M.L., Rickman R.C. Rasmussen's encephalitis: case presentation and discussion on the role of specific immune modulation. Brain Dev. 1998, 20:398.
39. Richardson P., Hideshima T., Anderson K. Thalidomide: emerging role in cancer medicine. Annu. Rev. Med. 2002, 53:629-657.
40. Rubio C., Custodio V., Juárez F., Paz C. Stimulation of the superior cerebellar peduncle during the development of amygdaloid kindling in rats. Brain Res. 2004, 1010:151-155.
41. Sikes R.W., Chronister R.B., White L.E. Origin of the direct hippocampus - anterior thalamic bundle in the rat: a combined horseradish peroxidase - golgi analysis. Exp. Neurol. 1977, 57:379-395.
42. Somers G.F. Pharmacological properties of thalidomide (alpha-phthalimido glutarimide), a new sedative hypnotic drug. Br. J. Pharmacol. Chemother. 1960, 15:111-116.
43. Sumrall A., Fredericks R., Berthold A., Shumaker G. Lenalidomide stops progression of multifocal epithelioid hemangioendothelioma including intracranial disease. J. Neurooncol. 2010, 97:275-277.
44. Teo S.K., Trigg N.J., Shaw M.E., Morgan J.M., Thomas S.D. Subchronic toxicity of thalidomide in rodents after 13 weeks of oral administration. Int. J. Toxicol. 1999, 18:337-352.
45. Tosi P., Zamagni E., Cellini C., Plasmati R., Cangini D., Tacchetti P., Perrone G., Pastorelli F., Tura S., Baccarani M., Cavo M. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur. J. Haematol. 2005, 74:212-216.
46. Wada J.A., Sato M., Corcoran M.E. Persistent seizure susceptibility and recurrent spontaneous seizures in kindled cats. Epilepsia 1974, 15:465-478.
47. Wauquier A., Zhou S. Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res. 1996, 24:73-77.
48. Zhang L., Qu Y., Tang J., Chen D., Fu X., Mao M., Mu D. PI3K/Akt signaling pathway is required for neuroprotection of thalidomide on hypoxic-ischemic cortical neurons in vitro. Brain Res. 2010, 1357:157-165.